The Ultimaster Biodegradable-Polymer Sirolimus-Eluting Stent: An Updated Review of Clinical Evidence

The Ultimaster coronary stent system (Terumo Corporation, Tokyo, Japan) represents a new iteration in drug-eluting stent (DES) technology that has recently received the Conformité Européenne (CE) mark approval for clinical use. The Ultimaster is a thin-strut, cobalt chromium, biodegradable-polymer,...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2016-09, Vol.17 (9), p.1490-1490
Main Authors: Chisari, Alberto, Pistritto, Anna Maria, Piccolo, Raffaele, La Manna, Alessio, Danzi, Gian Battista
Format: Article
Language:English
Subjects:
Angioplasty, Balloon - adverse effects
Angioplasty, Balloon - methods
Biodegradable Plastics - adverse effects
Biodegradable Plastics - chemistry
biodegradable polymer drug eluting stent
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
coronary stent
Drug-Eluting Stents - adverse effects
Humans
new-generation DES
Review
Sirolimus - administration & dosage
sirolimus-eluting stent
Ultimaster stent
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Ultimaster coronary stent system (Terumo Corporation, Tokyo, Japan) represents a new iteration in drug-eluting stent (DES) technology that has recently received the Conformité Européenne (CE) mark approval for clinical use. The Ultimaster is a thin-strut, cobalt chromium, biodegradable-polymer, sirolimus-eluting coronary stent. The high elasticity of the biodegradable-polymer (PDLLA-PCL) and the abluminal gradient coating technology are additional novel features of this coronary device. The Ultimaster DES has undergone extensive clinical evaluation in two studies: The CENTURY I and II trials. Results from these two landmark studies suggested an excellent efficacy and safety profile of the Ultimaster DES across several lesion and patient subsets, with similar clinical outcomes to contemporary, new-generation DES. The aim of this review is to summarize the rationale behind this novel DES technology and to provide an update of available evidence about the clinical performance of the Ultimaster DES.
ISSN:1422-0067
1422-0067
DOI:10.3390/ijms17091490